Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A Pharmacoepidemiologic Study

Pierre-Marie Morice; Basile Chrétien; Angélique Da Silva; Charles Dolladille; Joachim Alexandre

doi:10.1001/jamaoncol.2021.4672

Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A Pharmacoepidemiologic Study

JAMA Oncol. 2021 Dec 1;7(12):1899-1900. doi: 10.1001/jamaoncol.2021.4672.

Authors

Pierre-Marie Morice¹, Basile Chrétien², Angélique Da Silva³, Charles Dolladille⁴, Joachim Alexandre⁴

Affiliations

¹ French National Institute of Health and Medical Research (INSERM) U1086 Interdisciplinary Research Unit for Cancers Prevention and Treatment (ANTICIPE), François Baclesse Comprehensive Cancer Center, Normandie University, University of Caen Normandy (UNICAEN), Unicancer, Caen, France.
² Pharmacoepidemiology Unit, Department of Pharmacology, Pharmacovigilance Regional Center, Caen University Hospital, France.
³ Breast Cancer Unit, François Baclesse Comprehensive Cancer Center, Caen, France.
⁴ Department of Pharmacology, Caen University Hospital, INSERM U1086 ANTICIPE, Normandie University, UNICAEN, Caen, France.

Abstract

This cross-sectional study uses pharmacovigilance data to investigate the occurrence of pancytopenia among patients with cancer treated with poly(adenosine diphosphate–ribose) polymerase inhibitors and examines the clinical features of pancytopenia related to these drugs.

MeSH terms

Adenosine Diphosphate
Humans
Neoplasms* / complications
Neoplasms* / drug therapy
Neoplasms* / epidemiology
Pancytopenia* / chemically induced
Pancytopenia* / epidemiology
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Ribose

Substances

Poly(ADP-ribose) Polymerase Inhibitors
Adenosine Diphosphate
Ribose